Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Revenue

In the year 2023, Inhibikase Therapeutics had annual revenue of $260.50K with 111.03% growth. Revenue in the quarter ending December 31, 2023 was $1.00, a -100.00% decrease year-over-year.

• Revenue (ttm): $260.50K
• Revenue Growth: +111.03%
• P/S Ratio: 42.52
• Revenue / Employee: $32,563
• Employees: 8
• Market Cap: 11.08M USD

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	260.50K	137.06K	111.03%
Dec 31, 2022	123.44K	-2.98M	-96.02%
Dec 31, 2021	3.10M	2.40M	343.92%
Dec 31, 2020	698.47K	-424.27K	-37.79%
Dec 31, 2019	1.12M	-2.92M	-72.22%
Dec 31, 2018	4.04M	-	-

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.